Kalray’s OpenChip Warrant Overhang Could Reset Ownership and Pressure Shares

Kalray's latest capital update is a routine filing. The company published the total number of shares and voting rights as of February 27, 2026, showing 15,412,938 shares and 15,400,398 exercisable voting rights. This is standard disclosure, and the company confirms it has not implemented any threshold crossing clauses beyond legal requirements.

Yet the context makes this filing significant. It arrives in the wake of a radical 2025 transformation that saw the stock post a fourfold increase since the start of the year. The setup is now one of high expectations, where any new capital structure detail can move the needle. The update itself is clean, but it reveals a pre-announced dilution risk that the market's recent rally may not have fully priced in.

That risk stems from the strategic partnership with OpenChip, signed in spring 2025. The deal includes warrants that could see the Spanish partner increase its stake to about 20%, with a mechanism to reach a controlling 51% through a capital increase. The market consensus has been focused on the partnership's promise for revenue and margins, but the dilution mechanics are a separate, material variable. This update, by confirming the share count at a time of soaring stock prices, frames the potential future dilution in stark terms. It's a routine filing that underscores an expectation gap: the market has bought the rumor of a turnaround, but the reality of a capital structure that could be reset by a partner's options remains a hidden overhang.

The OpenChip Partnership: A Source of Revenue and a Dilution Engine

The partnership with OpenChip is the central pillar of Kalray's recent turnaround, delivering a clear and substantial revenue impact. On a comparable scope basis, the company's revenue from its core semiconductor business multiplied by four, jumping from €3.6 million in 2024 to €14.3 million in 2025. This growth is directly attributed to the deal, which includes a non-exclusive license for €4 million and a services agreement worth about €10 million. For the market, this is a classic "beat and raise" scenario: the revenue print was strong, and it validated the strategic pivot to an IP-licensing model. The partnership reset expectations, moving the stock from survival mode to growth narrative.

Yet this positive financial engine introduces a significant, pre-announced dilution risk that the market's recent rally may not have fully priced in. The OpenChip agreement includes warrants that, if exercised, would see the Spanish partner increase its stake to about 20% of Kalray. The mechanics are specific: the warrants are exercisable at a price of 0.69 EUR per share. This is a deeply discounted rate relative to the stock's current trading level, creating a direct dilution path for existing shareholders.

The risk escalates further with a capital increase mechanism. The agreement includes a provision that could allow OpenChip to reach a controlling 51% stake, based on the average share price of the three sessions preceding the agreement. This is a powerful reset button. If OpenChip chooses to exercise its options and trigger this capital increase, it could fundamentally alter the ownership structure and ownership economics of the company. The market has been focused on the revenue and margin promise of the partnership, but the dilution mechanics are a separate, material variable that introduces a layer of uncertainty and potential overhang.

The bottom line is a stark expectation gap. The OpenChip deal has delivered a fourfold revenue beat, which is priced in and celebrated. But the dilution engine it sets in motion-a warrant at a discount and a path to control-is a hidden cost that the market's recent pop may not have accounted for. This creates a tension between the near-term financial improvement and the longer-term ownership risk.

The Expectation Gap: Priced-In Success vs. Future Dilution

The market has clearly priced in the success of Kalray's new business model. The stock's trajectory tells the story: it has posted a fourfold increase since the start of the year, climbing from a low of 0.402 EUR in spring 2025 to trade around 5.30 EUR in February 2026. This 1,266% rally occurred after the company confirmed a strongly positive EBITDA for 2025. In other words, the market has bought the rumor of a turnaround and is now celebrating the reality of a profitable pivot. The expectation gap has been closed on the financials.

Yet this spectacular run also highlights the stock's extreme volatility and the market's repeated misjudgments of the company's trajectory. The dizzying swings-from a peak of 52.40 EUR in 2021 to a nadir of 0.402 EUR in 2025-show a history of over-optimism followed by severe disappointment. This pattern leaves the stock vulnerable to a sharp correction if new risks materialize. The dilution engine set in motion by the OpenChip partnership is that risk.

The market's recent pop has focused on the revenue beat and margin expansion, but it has not fully priced in the mechanics that could reset ownership. The warrants exercisable at 0.69 EUR per share represent a direct dilution path at a discount to the current price. More importantly, the capital increase mechanism that could allow OpenChip to reach a controlling 51% stake is a potential overhang. If the partner chooses to exercise its options, it could trigger a significant share issuance, pressuring the stock.

The bottom line is a tension between a validated business model and an uncertain capital structure. The financials are priced in and strong. The dilution risk, however, remains a hidden variable that could easily become the new reality. Given the stock's history of volatility, a reset triggered by dilution fears is a plausible scenario that the current valuation may not adequately account for.

Catalysts and Risks: What Could Reset Expectations Now

The stock's recent run has been a pure "buy the rumor" play. The market has fully priced in the success of the IP licensing pivot, with the stock posting a fourfold increase since the start of the year. That leaves the company vulnerable to any operational shortfall. The primary risk is that the current high valuation, built on a single transformative partnership, lacks a broad enough foundation to withstand a stumble.

The key watchpoint for validation is execution. The company must sustain its strongly positive EBITDA and convert its licensing pipeline into consistent, recurring revenue. This is the move from "survival mode" to a scalable business. If Kalray can demonstrate that the OpenChip deal is the start of a durable revenue stream, not a one-off event, it could support the elevated price. The market has already bought the turnaround story; it now needs proof the story has legs.

On the other side of the ledger, the dilution risk remains a structural overhang. While the company has maintained its governance structure and avoided the kind of capital raises seen in some peers, the OpenChip warrants and capital increase mechanism are pre-announced. Any sign that the partnership is stalling or that OpenChip is considering its options could trigger a sharp correction, as the market reassesses the ownership and financial implications.

The bottom line is that the stock's path forward depends entirely on execution, not capital structure. The dilution mechanics are a known variable, but the company's ability to deliver on its financial promises will be the catalyst that either confirms the new valuation or resets it.